Why Is Tesamorelin So Hard to Find? [Explained for 2026]

If you or a loved one has been prescribed tesamorelin — sold under the brand names Egrifta SV and Egrifta WR — you may have quickly discovered that this is not the kind of medication you can just pick up at your corner pharmacy. Patients regularly report confusion, delays, and frustration trying to fill their prescriptions. In this article, we explain exactly why tesamorelin is so difficult to find, what changed in 2025, and what you can do to get your medication faster.

What Is Tesamorelin and Who Is It For?

Tesamorelin is a synthetic growth hormone-releasing factor (GHRF) analog. It is the only FDA-approved medication in the United States specifically indicated for the reduction of excess abdominal fat — called visceral adipose tissue (VAT) — in HIV-infected adults with lipodystrophy. Lipodystrophy is a condition where the body stores and redistributes fat in abnormal ways, often causing a buildup of hard belly fat that does not respond well to diet or exercise alone.

Tesamorelin was first approved in 2010 under the original brand name Egrifta. It has since gone through two reformulations: Egrifta SV (approved 2019) and Egrifta WR (approved March 2025). The manufacturer, Theratechnologies, markets these as specialty biologics — a category of drugs that come with significant access hurdles.

Why Is Tesamorelin Only Available at Specialty Pharmacies?

Tesamorelin is not stocked at your typical retail pharmacy like CVS, Walgreens, or Walmart. It is only dispensed through specialty pharmacies — a network of pharmacies that handle complex, high-cost medications requiring special handling, storage, and patient management. Here's why:

Special storage requirements: Egrifta SV vials must be refrigerated before reconstitution. Egrifta WR can be stored at room temperature, but still requires careful handling as a biologic product.

Injection training required: Patients must learn how to reconstitute and inject the medication. Specialty pharmacies coordinate with the THERA Patient Support program to provide nurse navigator training.

Insurance coordination: Specialty pharmacies manage the prior authorization process, appeals, and insurance benefit verification on behalf of patients.

Payer restrictions: Insurance plans often require patients to use specific in-network specialty pharmacies. You may not be able to use just any specialty pharmacy.

Prior Authorization: The Biggest Bottleneck

Even after a doctor writes a prescription for tesamorelin, most insurance plans require prior authorization (PA) before they will cover it. This means the insurer needs to review your case and confirm that the drug is medically necessary for you specifically. This process typically takes 2 to 4 weeks, and it can be denied the first time around, requiring an appeal.

For tesamorelin, the prior authorization criteria are strict. Insurers typically require documentation of an HIV diagnosis, confirmed lipodystrophy with excess visceral adipose tissue (often verified by CT or MRI imaging), and baseline waist circumference measurements. Some plans also require evidence that diet and lifestyle modifications were attempted first. This documentation-heavy process is a primary reason patients wait weeks or even months before getting their first prescription filled.

The 2024-2025 Egrifta SV Supply Disruption

On top of the existing access challenges, Egrifta SV experienced a supply disruption that created additional uncertainty for patients. Theratechnologies worked with the FDA to resolve the issue, and on April 8, 2025, the FDA approved a Prior Approval Supplement (PAS) to the Egrifta SV biologics license application — allowing the company to resume normal distribution.

The timing of the supply resolution coincided with the FDA approval of Egrifta WR in March 2025 — a newer formulation that requires only weekly reconstitution instead of daily reconstitution. As of September 2025, specialty pharmacies have been stocking Egrifta WR, and it is gradually replacing Egrifta SV. Egrifta SV remains available during a transitional period as insurance plans add coverage for the newer formulation.

No Generic Available — That Drives Up the Price and Limits Your Options

There is no FDA-approved generic version of tesamorelin in the United States. Theratechnologies holds patent exclusivity on the branded product. As a result, the cash price for brand-name Egrifta SV or Egrifta WR is extremely high — typically $2,400 to $2,800 per month out of pocket.

Compounded tesamorelin is available from 503A and 503B compounding pharmacies at a lower cost, but compounded versions are not FDA-approved and may not be covered by insurance. Always discuss compounded tesamorelin with your doctor before pursuing this route.

What Can You Do If You Can't Find Tesamorelin?

Here are concrete steps you can take right now:

Enroll in the THERA Patient Support program: Call 1-833-23-THERA (1-833-238-4372). This program provides insurance verification, prior authorization assistance, co-pay support, and a dedicated nurse navigator.

Ask your doctor about Egrifta WR: If you are currently on Egrifta SV and having trouble getting it, ask your doctor about transitioning to Egrifta WR, which is now stocked by specialty pharmacies.

Use medfinder: medfinder calls pharmacies near you — including specialty pharmacies — to check which ones can fill your tesamorelin prescription. This saves you the time and frustration of calling pharmacies yourself.

Apply for the Patient Assistance Program: If you don't have insurance or your insurance won't cover tesamorelin, the THERA Patient Assistance Program may provide the medication at no cost for qualifying patients.

Ask about alternatives: If tesamorelin is unavailable or unaffordable, talk to your doctor about other options. See our guide on alternatives to tesamorelin if you can't fill your prescription.

The Bottom Line

Tesamorelin is hard to find because it is a specialty-only biologic with strict insurance requirements, no generic alternative, and a recent history of supply disruption. The good news is that Egrifta WR is now commercially available and the supply situation has stabilized. If you are struggling to get your prescription filled, the THERA Patient Support program and medfinder are your best starting points.